Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 receptor agonists. (Funded by Eli Lilly; ATTAIN-1 ClinicalTrials.gov number, NCT05869903.).
Authors
- Sean Wharton (ORCID: https://orcid.org/0000-0003-0111-1530)
- Suzanne Klise
- Sheryl Allen (ORCID: https://orcid.org/0000-0001-6862-4002)
- Lisa Macpherson (ORCID: https://orcid.org/0000-0003-3224-9233)
- Louis J. Aronne (ORCID: https://orcid.org/0000-0002-9890-9401)
- Bruno Halpern (ORCID: https://orcid.org/0000-0003-0973-5065)
- Nasreen Alfaris (ORCID: https://orcid.org/0000-0002-5851-8430)
- Alpana P. Shukla (ORCID: https://orcid.org/0000-0002-4763-2350)
- Andreea Ciudin (ORCID: https://orcid.org/0000-0001-5622-0203)
- Chunmei Zhou
- Adam Stefański (ORCID: https://orcid.org/0009-0001-7598-402X)
- Nadia N. Ahmad
- Koutaro Yokote
Institutions
- Universitat Autònoma de Barcelona (ES)
- Chiba University (JP)
- Eli Lilly (United States) (US)
- York University (CA)
- Cornell University (US)
- Instituto de Salud Carlos III (ES)
- King Fahd Medical City (SA)
- Universidade Nove de Julho (BR)
- Escuela Nacional de Sanidad (ES)
- Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (ES)
- Vall d'Hebron Institut de Recerca (ES)
- Vall d'Hebron Hospital Universitari (ES)
- START Clinic (CA)
- Weill Cornell Medicine (US)
- McMaster University (CA)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-09-16
- DOI
- https://doi.org/10.1056/nejmoa2511774
- Citations
- 44
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 61.36